Anixa Biosciences Inc. (NASDAQ: ANIX) reported survival data from its ongoing Phase 1 clinical trial of lira-cel, a CAR-T therapy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE